DE1204671B - Process for the preparation of 1beta-methyl-delta-5alpha-androstene-17beta-ols - Google Patents
Process for the preparation of 1beta-methyl-delta-5alpha-androstene-17beta-olsInfo
- Publication number
- DE1204671B DE1204671B DESCH33579A DESC033579A DE1204671B DE 1204671 B DE1204671 B DE 1204671B DE SCH33579 A DESCH33579 A DE SCH33579A DE SC033579 A DESC033579 A DE SC033579A DE 1204671 B DE1204671 B DE 1204671B
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- androsten
- androstene
- ols
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000001195 anabolic effect Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001548 androgenic effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- WKHJZIRDAONVML-UHFFFAOYSA-N dichloromethane;tetrachloromethane Chemical compound ClCCl.ClC(Cl)(Cl)Cl WKHJZIRDAONVML-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0025—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Description
BUNDESREPUBLIK DEUTSCHLANDFEDERAL REPUBLIC OF GERMANY
DEUTSCHESGERMAN
PATENTAMTPATENT OFFICE
Int. CL:Int. CL:
C07cC07c
Deutsche Kl.: 12 ο-25/04 German class: 12 ο -25/04
Nummer: 1204 671Number: 1204 671
Aktenzeichen: Sch 33579IV b/12 οFile number: Sch 33579IV b / 12 ο
Anmeldetag: 18. Juli 1963Filing date: July 18, 1963
Auslegetag: 11. November 1965Opening day: November 11, 1965
Gegenstand der Erfindung ist ein Verfahren zur Herstellung von l^-Methyl-zl2-5a-androsten-17^-olen der allgemeinen FormelThe invention relates to a process for the preparation of l ^ -Methyl-zl 2 -5a-androstene-17 ^ -ols of the general formula
CH3 CH 3
worin R1 Wasserstoff oder eine Acylgruppe und R2 eine niedere gesättigte oder ungesättigte Alkylgruppe bedeutet.wherein R 1 is hydrogen or an acyl group and R 2 is a lower saturated or unsaturated alkyl group.
Das erfindungsgemäße Verfahren besteht darin, daß man in l^-Methyl-J2-5a-androsten-17-on (V) in an sich bekannter Weise entweder durch Grignardierung eine 17a-ständige Alkylgruppe einfuhrt oderThe process according to the invention consists in introducing a 17a-alkyl group into l ^ -methyl-J 2 -5a-androsten-17-one (V) in a manner known per se either by Grignardation or
CH3 CH 3
Verfahren zur Herstellung von Ij3-Methyl-
A 2-5 a-androsten-17 ß-cAsn. Process for the preparation of Ij3-methyl-
A 2 -5 a-androstene-17 ß-cAsn.
Anmelder:Applicant:
Schering Aktiengesellschaft,Schering Aktiengesellschaft,
Berlin N 65, Müllerstr. 170/172Berlin N 65, Müllerstr. 170/172
Als Erfinder benannt:Named as inventor:
Dr. Hans Müller,Dr. Hans Müller,
Dr. Rudolf Wiechert, BerlinDr. Rudolf Wiechert, Berlin
eine analog eingeführte 17a-Äthinylgruppe anschließend zur Vinylgruppe reduziert und gegebenenfalls die erhaltenen freien 17/3-Hydroxyverbindungen in an sich ebenfalls bekannter Weise acyliert.followed by an analogously introduced 17a-ethynyl group reduced to the vinyl group and optionally the free 17/3 hydroxy compounds obtained in acylated in a manner also known per se.
OHOH
CH3 CH 3
CH3 CH 3
IXIX
Das hierbei als Ausgangsstoff· dienende, in der Literatur bisher nicht beschriebene 1/3-Methylzl2-5a-androsten-17-on (V) kann nach an sich bekannten Methoden hergestellt werden, indem man z.B. lß-Methyl-5a-androstan-17/3-ol-3-on-17-acetat(I) mit Natriumborhydrid zum Gemisch der beiden 3 - epimeren iß - Methyl - 5a - androstan - 3,Πβ - diol-17-acetate (II) reduziert. Dieses Gemisch wird ohne vorherige Trennung tosyliert und über neutrales Aluminiumoxyd filtriert, wobei l/S-Methyl-zl2-5a-androsten-17/9-ol-17-acetat (III) entsteht. Nach Verseifung der 17-Acetoxygruppe erhält man durch Oxydation des freien lß-Methyl-,/l2-5a-androsten-17/3-ols (IV) mittels Chromschwefelsäure das gewünschte l/?-Methyl-,d2-5a-androsten-17-on (V). The 1/3-methylzl 2 -5a-androsten-17-one (V) which serves as the starting material and has not yet been described in the literature can be prepared by methods known per se by, for example, lß-methyl-5a-androstane 17/3-ol-3-one-17-acetate (I) reduced with sodium borohydride to a mixture of the two 3 - epimeric iß - methyl - 5a - androstane - 3, Πβ - diol-17-acetate (II). This mixture is tosylated without prior separation and filtered through neutral aluminum oxide, 1 / S-methyl-zl 2 -5a-androstene-17/9-ol-17-acetate (III) being formed. After saponification of the 17-acetoxy group, oxidation of the free lβ-methyl-, / l 2 -5a-androstene-17/3-ol (IV) with chromosulfuric acid gives the desired l / γ-methyl-, d 2 -5a-androstene -17-on (V).
Für die Herstellung dieser Verbindung wird im Rahmen der vorliegenden Erfindung Schutz nicht begehrt.For the preparation of this compound, protection is not given in the context of the present invention desired.
Die erfindungsgemäß herstellbaren neuen Verbindungen sind wertvolle Pharmazeutika.The new compounds which can be prepared according to the invention are valuable pharmaceuticals.
509 737/410509 737/410
Das l^na-Dimethyl-^-Sa-androsten-n^-ol (VI) ist, wie die nachfolgende Tabelle zeigt, ein peroral ganz außerordentlich stark wirksames Anabolikum ohne nennenswerte androgene Nebenwirkung. Die perorale anabole und androgene Wirksamkeit wurde nach Standardmethoden an der kastrierten männlichen Ratte im Levator-ani-Test bzw. im Samenblasentest, bezogen auf 17a-Methyl-zI4-androsten-17/?-ol-3-on, als Standardsubstanz bestimmt.The l ^ na-dimethyl - ^ - Sa-androsten-n ^ -ol (VI) is, as the following table shows, an extremely effective anabolic perorally without any noteworthy androgenic side effects. The peroral anabolic and androgenic activity was determined according to standard methods on the castrated male rat in the levator-ani test or in the seminal vesicle test, based on 17a-methyl-zI 4 -androsten-17 /? - ol-3-one, as the standard substance.
Substanzsubstance
a) 17a-Methylzl4-androsten-17|S-ol-3-on a) 17a-Methylzl 4 -androsten-17 | S-ol-3-one
b) 17a-Methyl-J2-5a-androsten-
Πβ-όΡ)
b) 17a-methyl-J 2 -5a-androsten-
Πβ-όΡ)
c) la,17a-Dimethyl-
Δ 2-5«-androsten-Πβ-οΨ)
c) la, 17a-dimethyl
Δ 2 -5 «-android- Πβ-οΨ)
d) Ij8,17a-Dimethyl-
<d2-5a-androsten-
Πβ-ολ d) Ij8,17a-dimethyl
<d 2 -5a-androsten-
Πβ-ολ
Verhältnis anabol zu androgenRatio anabolic to androgenic
1818th
7070
*) Vgl. Chem. and Ind., 1961, S. 1962; USA.-Patentschrift*) See Chem. And Ind., 1961, p. 1962; U.S. Patent
2 996 524,
2) Vgl. deutsche Patentanmeldung Sch 33126 IVb/12 ο (deutsche
Auslegeschrift 1199 767).2,996,524,
2 ) See German patent application Sch 33126 IVb / 12 ο (German Auslegeschrift 1199 767).
Man sieht, daß d) nicht nur gegenüber der entsprechenden 1-Desmethylverbindung b), sondern sogar gegenüber dem entsprechenden la-Epimeren c) nicht nur eine unvorhersehbare außerordentliche Verstärkung der anabolen Wirksamkeit, sondern gleichzeitig auch eine überraschend günstige Verschiebung des Wirkungsverhältnisses anabol zu androgen zeigt.You can see that d) not only in relation to the corresponding 1-desmethyl compound b), but even compared to the corresponding la epimer c) not only an unpredictable extraordinary increase in anabolic effectiveness, but at the same time a surprisingly favorable shift in the anabolic to androgenic ratio of action shows.
Das l^-Methyl-17a-äthinyl-zl2-5a-androsten-17^-ol (VII) besitzt die Fähigkeit, die Gonadotropinausschüttung zu hemmen, da sich nach seiner Applikation eine. Hemmwirkung auf das Wachstum von Testes und Prostata beobachten läßt.The l ^ -Methyl-17a-äthinyl-zl 2 -5a-androsten-17 ^ -ol (VII) has the ability to inhibit the release of gonadotropins, since after its application a. Inhibitory effect on the growth of testes and prostate can be observed.
Zur gekühlten Grignardlösung, hergestellt aus 3,94 g Magnesiumspänen in 44 ml absolutem Äther und 10,2 ml Methyljodid in 28,4 ml absolutem Äther, werden 3,6 g l^-Methyl-J2-5a-androsten-17-on (V) in 130 ml absolutem Benzol zugetropft und 4 Stunden bei Raumtemperatur unter Stickstoff gerührt. Dann wird unter Außenkühlung mit Eis vorsichtig konzentrierte wäßrige Ammoniumchloridlösung zugesetzt; es wird mit verdünnter Chlorwasserstoffsäure angesäuert und mit Äther extrahiert. Die ätherische Phase wird neutral gewaschen, getrocknet und eingedampft. Der kristalline Rückstand wird über Silicagel (10% Wassergehalt) chromatographiert. Durch Eluieren mit Tetrachlorkohlenstoff und mit Methylenchlorid—Tetrachlorkohlenstoff (3 : 1) erhält man 2,75 g l/?,17a-Dimethyl-zl2-5a-androsten- Ylß-o\ (VI), die aus Pentan umkristallisiert bei 146 bis 147°C schmelzen.To the cooled Grignard solution, prepared from 3.94 g of magnesium shavings in 44 ml of absolute ether and 10.2 ml of methyl iodide in 28.4 ml of absolute ether, 3.6 gl ^ -Methyl-I 2 -5a-androsten-17-one ( V) was added dropwise in 130 ml of absolute benzene and stirred for 4 hours at room temperature under nitrogen. Then, with external cooling with ice, concentrated aqueous ammonium chloride solution is carefully added; it is acidified with dilute hydrochloric acid and extracted with ether. The ethereal phase is washed neutral, dried and evaporated. The crystalline residue is chromatographed over silica gel (10% water content). Eluting with carbon tetrachloride and with methylene chloride-carbon tetrachloride (3: 1) gives 2.75 gl / ?, 17a-dimethyl-zl 2 -5a-androsten- ylß-o \ (VI), which recrystallizes from pentane at 146 to 147 Melting ° C.
Das gekühlte Grignardreagenz aus 936 mg Magnesiumspänen in 9,6 ml absolutem Tetrahydrofuran und 2,92 ml Äthylbromid in 9,2 ml absolutem Tetrahydrofuran wird zu 16 ml absolutem Tetrahydrofuran gegeben, durch das vorher 20 Minuten Acetylen durchgeleitet worden ist. Dabei steigt die" Temperatur auf 45°C an. Es wird weiter Acetylen eingeleitet, bis die Temperatur wieder fällt. Dann werden 450 mgThe cooled Grignard reagent from 936 mg of magnesium turnings in 9.6 ml of absolute tetrahydrofuran and 2.92 ml of ethyl bromide in 9.2 ml of absolute tetrahydrofuran becomes 16 ml of absolute tetrahydrofuran given, through which acetylene has previously been passed for 20 minutes. The "temperature" rises at 45 ° C. Acetylene continues to be passed in until the temperature drops again. Then 450 mg
ίο lß-Methyl-zl2-5a-androsten-17-on (V) in 9,6 ml absolutem Tetrahydrofuran zugetropft. Während des Zutropfens wird immer noch Acetylen eingeleitet. Dann wird das Reaktionsgemisch unter Stickstoff und unter Rühren 21 Stunden im 70° C heißen ölbad erhitzt. Nach Abkühlung auf 5° C wird konzentrierte wäßrige Ammoniumchloridlösung langsam zugesetzt, bis keine Reaktion mehr eintritt. Nun wird mit Äther extrahiert, die organische Phase mit Wasser neutral gewaschen, über Natriumsulfat getrocknet, im Vakuum zur Trockne eingeengt und der Rückstand über Silicagel (10% Wassergehalt) chromatographiert. Durch Eluieren mit gleichen Teilen Tetrachlorkohlenstoff und Methylenchlorid erhält man 260mg l/S-Methyl-17a-äthinyl-zl2-5a-androsten- Ylß-oX (VII); F. 118 bis 119°C (aus Pentan).ίο lß-methyl-zl 2 -5a-androsten-17-one (V) in 9.6 ml of absolute tetrahydrofuran was added dropwise. Acetylene is still being introduced during the dropwise addition. The reaction mixture is then heated under nitrogen and with stirring in a 70 ° C. oil bath for 21 hours. After cooling to 5 ° C., concentrated aqueous ammonium chloride solution is slowly added until no further reaction occurs. It is then extracted with ether, the organic phase washed neutral with water, dried over sodium sulfate, evaporated to dryness in vacuo and the residue chromatographed over silica gel (10% water content). Eluting with equal parts of carbon tetrachloride and methylene chloride gives 260 mg of 1 / S-methyl-17a-äthinyl-zl 2 -5a-androsten- Ylß-oX (VII); M.p. 118 to 119 ° C (from pentane).
312 mg des wie vorstehend erhaltenen 1/S-Methyl-17a-äthinyl-zl2-5a-androsten-17jS-ols (VII) werden in 50 ml Pyridin gelöst und unter Zusatz von 60 mg 5%igem Palladium-Kohle-Katalysator bis zur Aufnähme von 1 mMol Wasserstoff hydriert. Es wird dann vom Katalysator abfiltriert und die Lösung im Vakuum zur Trockne eingeengt. Der Rückstand besteht aus 160 mg l^-Methyl-17a-vinyl-zl2-5a-androsten-17/ί-οΙ (VIII); F. 118 bis 119°C und 129 bis 130°C (aus Pentan; Kristallpolyamorphie).312 mg of the 1 / S-methyl-17a-äthinyl-zl 2 -5a-androsten-17jS-ols (VII) obtained as above are dissolved in 50 ml of pyridine and, with the addition of 60 mg of 5% palladium-carbon catalyst, up to hydrogenated to absorb 1 mmol of hydrogen. The catalyst is then filtered off and the solution is concentrated to dryness in vacuo. The residue consists of 160 mg of l ^ -Methyl-17a-vinyl-zl 2 -5a-androsten-17 / ί-οΙ (VIII); M.p. 118 to 119 ° C and 129 to 130 ° C (from pentane; crystal polyamorphism).
Zur gekühlten Grignardlösung, hergestellt aus 3,94 g Magnesiumspänen in 44 ml absolutem Äther und 10,2 ml Äthyljodid in 28,4 ml absolutem Äther, werden 3,6 g lß-Methyl-zl2-5a-androsten-17-on (V) in 130 ml absolutem Benzol zugetropft und 6 Stunden bei Raumtemperatur unter Stickstoff gerührt. Dann wird unter Außenkühlung mit Eis konzentrierte wäßrige Ammoniumchloridlösung zugesetzt; es wird mit verdünnter Chlorwasserstoffsäure angesäuert und mit Äther extrahiert. Die ätherische Phase wird neutral gewaschen, getrocknet und eingedampft. Der Rückstand wird über Silicagel mit Tetrachlorkohlenstoff und mit Methylenchlorid— Tetrachlorkohlenstoff (3 : 1) chromatographiert. Man erhält 1,2 g l/?-Methyl-17a-äthyl-/l2-5a-androsten-17ß-ol (IX); F. 78 bis 80°C (aus Pentan).To the cooled Grignard solution, prepared from 3.94 g of magnesium shavings in 44 ml of absolute ether and 10.2 ml of ethyl iodide in 28.4 ml of absolute ether, 3.6 g of lß-methyl-zl 2 -5a-androsten-17-one ( V) was added dropwise in 130 ml of absolute benzene and stirred for 6 hours at room temperature under nitrogen. Then concentrated aqueous ammonium chloride solution is added with external cooling with ice; it is acidified with dilute hydrochloric acid and extracted with ether. The ethereal phase is washed neutral, dried and evaporated. The residue is chromatographed over silica gel with carbon tetrachloride and with methylene chloride-carbon tetrachloride (3: 1). 1.2 gl /? - methyl-17a-ethyl- / l 2 -5a-androsten-17ß-ol (IX) are obtained; F. 78 to 80 ° C (from pentane).
1 g l£,17a-Dimethyl-./l2-5a-androsten-17jS-ol wird in 5 ml Pyridin mit 5 ml Acetanhydrid 4 Stunden auf 130 bis 140°C erhitzt. Nach dem Abkühlen wird das Reaktionsgemisch in eine eisgekühlte Natriumchloridlösung eingerührt. Der dabei erhaltene halbfeste Niederschlag wird abfiltriert, mit Wasser neutral gewaschen und dann in Essigester gelöst. Die Essigesterlösung wird nochmals mit Wasser gewaschen, mit Aktivkohle behandelt, über Natriumsulfat getrocknet und nach Filtrieren bis zur Trockne eingeengt. Man erhält so 850 mg semikristallines l|8,17a-Dimethyl-/l2-5a-androsten-17/3-ol-17-acetat, [a]f = -2° (CHCl3; -c = 1,07).1 gl £, 17a-dimethyl -. / L 2-5a-androstene-17-ol S j is heated in 5 ml of pyridine with 5 ml of acetic anhydride for 4 hours at 130 to 140 ° C. After cooling, the reaction mixture is stirred into an ice-cold sodium chloride solution. The semi-solid precipitate obtained is filtered off, washed neutral with water and then dissolved in ethyl acetate. The ethyl acetate solution is washed again with water, treated with activated charcoal, dried over sodium sulfate and, after filtration, concentrated to dryness. This gives 850 mg of semicrystalline 1 | 8,17a-dimethyl- / 1 2 -5a-androstene-17/3-ol-17-acetate, [a] f = -2 ° (CHCl 3 ; -c = 1.07 ).
Claims (1)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE650709D BE650709A (en) | 1963-07-18 | ||
| DESCH33579A DE1204671B (en) | 1963-07-18 | 1963-07-18 | Process for the preparation of 1beta-methyl-delta-5alpha-androstene-17beta-ols |
| GB28146/64A GB1045036A (en) | 1963-07-18 | 1964-07-08 | New 1ª-methyl-í¸-5ª-androsten-17ª-ols and process for their manufacture |
| NL6408171A NL6408171A (en) | 1963-07-18 | 1964-07-17 | |
| FR982012A FR1433328A (en) | 1963-07-18 | 1964-07-17 | New derivatives of 1beta-methyl-androstane and their preparation |
| FR991646A FR4257M (en) | 1963-07-18 | 1964-10-16 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DESCH33579A DE1204671B (en) | 1963-07-18 | 1963-07-18 | Process for the preparation of 1beta-methyl-delta-5alpha-androstene-17beta-ols |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1204671B true DE1204671B (en) | 1965-11-11 |
Family
ID=7432849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DESCH33579A Pending DE1204671B (en) | 1963-07-18 | 1963-07-18 | Process for the preparation of 1beta-methyl-delta-5alpha-androstene-17beta-ols |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE650709A (en) |
| DE (1) | DE1204671B (en) |
| FR (2) | FR1433328A (en) |
| GB (1) | GB1045036A (en) |
| NL (1) | NL6408171A (en) |
-
0
- BE BE650709D patent/BE650709A/xx unknown
-
1963
- 1963-07-18 DE DESCH33579A patent/DE1204671B/en active Pending
-
1964
- 1964-07-08 GB GB28146/64A patent/GB1045036A/en not_active Expired
- 1964-07-17 FR FR982012A patent/FR1433328A/en not_active Expired
- 1964-07-17 NL NL6408171A patent/NL6408171A/xx unknown
- 1964-10-16 FR FR991646A patent/FR4257M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR4257M (en) | 1966-07-04 |
| BE650709A (en) | |
| NL6408171A (en) | 1965-01-19 |
| GB1045036A (en) | 1966-10-05 |
| FR1433328A (en) | 1966-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2035738A1 (en) | New androgens and methods of making them | |
| DE2714680A1 (en) | PROCESS FOR THE PRODUCTION OF 7-KETO-DELTA HIGH 5 STEROIDS | |
| DE1204671B (en) | Process for the preparation of 1beta-methyl-delta-5alpha-androstene-17beta-ols | |
| DE1518469A1 (en) | Process for the preparation of B-homoesterene compounds substituted in 3,7,17 positions | |
| DE2137557C3 (en) | Process for the production of Acyloxy Delta 4 androstenen or ostrenen | |
| DE1199767B (en) | Process for the preparation of 1alpha-methyl-A2-5alpha-androsten-17beta-ols | |
| DE1227912B (en) | Process for the preparation of therapeutically active steroid compounds | |
| CH495965A (en) | 16alpha-alkyl estrane derivs | |
| DE2438424C2 (en) | Process for the production of equilenin and equilenin derivatives | |
| DE1240076B (en) | Process for the production of 11-keto-5alpha, 9beta, 10alpha-steroids of the 19-norandrostan- (oestran-) - or. -pregnan sequence | |
| AT269378B (en) | Process for the preparation of new 6-hydroxy- or -acyloxymethyl-3-oxo-4,6-diene steroids | |
| AT228410B (en) | Process for the production of new 6-methyl-3-oxo-4, 6-diene steroids | |
| DE1001985C2 (en) | Process for the production of 7-ketosteroids of the ergostan and cholanic series which are unsaturated in the 8- and 9 (11) -position | |
| DE1493163C3 (en) | nalpha-ethynyl-ie-methyl-delta high 4-oestrene-3 beta-17 betadiols, processes for their preparation and agents containing them | |
| AT233184B (en) | Process for the preparation of 3-oxo-Δ <1,4> steroids | |
| DE1468632C (en) | öalpha Acetylthio 4 en 3 on steroids and process for their production | |
| DE1210818B (en) | Process for the preparation of 1,1-ethylene-17alpha-alkyl-delta 2-5alpha-androsten-17beta-ols and their 17-esters | |
| DE1122948B (en) | Process for the production of 7,17ª ‡ -dimethylsteroidverbindungen of the androstane series | |
| DE1232140B (en) | Process for the preparation of 2, 19-cyclo-3-keto steroids of the androstane series | |
| DE1272289B (en) | Process for the preparation of 19-hydroxy-androst-4-en-3, 17-dione | |
| DE1227901B (en) | Process for the production of 3-deoxysteroids of the androstane series | |
| DE1226574B (en) | Process for the preparation of 1,2alpha-methylene-5alpha-androstane derivatives | |
| DE1188591B (en) | Process for the preparation of 6beta-nitro-3alpha, 5alpha-cycloandrostan-17-one or delpetersaureesters of 3beta-hydroxyandrost-5-en-17-one | |
| DE1300943B (en) | Process for the preparation of 3-deoxygonane compounds | |
| DE1215147B (en) | Process for the production of 19 norsteroids of the androstane series |